08:00 , Nov 21, 2005 |  BioCentury  |  Product Development

One-two punch against flu

Developing an influenza vaccine that can protect the population from all strains of the virus is a Holy Grail for vaccine developers. Acambis plc , best known for its smallpox vaccine efforts, last week provided...
07:00 , May 30, 2005 |  BC Week In Review  |  Company News

ImVisioN GmbH management update

ImVisioN GmbH , Hanover, Germany   Business: Autoimmune   Hired: Martin Steiner as CEO, formerly CEO of Apovia AG  ...
00:44 , May 24, 2005 |  BC Extra  |  Company News

ImVisionN names Steiner CEO

ImVisioN (Hanover, Germany) hired Martin Steiner as CEO. Previously, he was CEO of Apovia (Martinsried, Germany). ImVisioN's IVN201 is a peptide vaccine that is in preclinical development for cat allergies and is expected to start...
08:00 , Mar 7, 2005 |  BC Week In Review  |  Company News

Apovia, Lorantis deal

Lorantis acquired HBV vaccine technology from Apovia, which is insolvent. The deal includes CV-1831, an HBV core antigen that uses the RC-529 adjuvant from Corixa Corp. (CRXA, Seattle, Wash.). CRXA and Apovia were developing the...
07:00 , Aug 9, 2004 |  BioCentury  |  Finance

Ebb & Flow

Six substantial venture rounds - three each in the U.S. and Europe - brought in $166.1 million last week, but the differences between the rounds illustrates the continued lag in European funding. Thus, three U.S....
07:00 , Sep 1, 2003 |  BC Week In Review  |  Company News

Apovia, National Institutes of Health deal

The NIH granted Apovia an exclusive worldwide license to patents covering conjugate vaccines against nontypeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis. The patents relate to Apovia's OtiVax vaccine against NTHi and M. catarrhalis to prevent...
07:00 , Aug 25, 2003 |  BC Week In Review  |  Company News

Apovia, Corixa deal

Under a co-development deal, CRXA granted Apovia commercial rights to its RC-529 synthetic adjuvant for use in an undisclosed therapeutic vaccine. Apovia develops vaccines to prevent and treat infectious diseases based on a modified hepatitis...
07:00 , Sep 16, 2002 |  BC Week In Review  |  Clinical News

MalariVax: Phase I

Apovia started a U.K. Phase I trial of MalariVax in 24 healthy volunteers. Apovia AG , Martinsried, Germany   Product: MalariVax   Business: Infectious diseases   Therapeutic category: Immune stimulation   Target: Plasmodium falciparum  ...
07:00 , Sep 16, 2002 |  BC Week In Review  |  Clinical News

MalariVax: Phase I

Apovia started a U.S. Phase I trial of MalariVax in 48 healthy volunteers. Apovia AG , Martinsried, Germany   Business: Infectious diseases   Product: MalariVax   Therapeutic category: Immune stimulation   Description: Malaria vaccine directed...
07:00 , Apr 22, 2002 |  BC Extra  |  Financial News

Apovia raises EUR19 million

Infectious disease company Apovia raised EUR19million ($17.1 million) in a private round led by Heidelberg Innovation. Other investors included Genavent; SG Asset Management; VCH Equity Group; 3i; Global Life Science Partners; and Oxford BioScience Partners....